<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Oral Cancer News &#187; EGFR</title>
	<atom:link href="http://oralcancernews.org/wp/tag/egfr/feed/" rel="self" type="application/rss+xml" />
	<link>http://oralcancernews.org/wp</link>
	<description>The Oral Cancer Foundation News Archive</description>
	<lastBuildDate>Tue, 27 Jul 2010 19:28:38 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.9.2</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>ASCO: Antibody improves head and neck cancer results</title>
		<link>http://oralcancernews.org/wp/asco-antibody-improves-head-and-neck-cancer-results/</link>
		<comments>http://oralcancernews.org/wp/asco-antibody-improves-head-and-neck-cancer-results/#comments</comments>
		<pubDate>Sun, 06 Jun 2010 14:24:13 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[EGFR]]></category>
		<category><![CDATA[epidermal growth factor receptor]]></category>
		<category><![CDATA[erbitux]]></category>
		<category><![CDATA[human papillomavirus]]></category>
		<category><![CDATA[monoclonal antibody]]></category>
		<category><![CDATA[nimotuzumab]]></category>
		<category><![CDATA[toxicity]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=8800</guid>
		<description><![CDATA[
			
				
			
		
Source: www.medpagetoday.com
Author:  Michael Smith, North American Correspondent, MedPage Today
A novel antibody improved outcomes for patients with advanced and inoperable squamous cell carcinoma of the head and neck, researchers reported.
Combined with radiation or chemoradiation, the substance &#8212; a fully humanized monoclonal antibody dubbed nimotuzumab &#8212; significantly outperformed either modality alone in an open-label randomized trial, [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/asco-antibody-improves-head-and-neck-cancer-results/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Nano-bio-chip sensor platform for examination of oral exfoliative cytology</title>
		<link>http://oralcancernews.org/wp/nano-bio-chip-sensor-platform-for-examination-of-oral-exfoliative-cytology/</link>
		<comments>http://oralcancernews.org/wp/nano-bio-chip-sensor-platform-for-examination-of-oral-exfoliative-cytology/#comments</comments>
		<pubDate>Sun, 04 Apr 2010 16:12:06 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[brush biopsy]]></category>
		<category><![CDATA[EGFR]]></category>
		<category><![CDATA[epidermal growth factor receptor]]></category>
		<category><![CDATA[exfoliative cytology]]></category>
		<category><![CDATA[nano-bio-chip]]></category>
		<category><![CDATA[NBC]]></category>
		<category><![CDATA[oral tumorigenesis]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=8272</guid>
		<description><![CDATA[
			
				
			
		
Source: Cancer Prevention Research 3(4); 518-28, March 23, 2010
Authors: SE Weigum et al.
Oral cancer is a deadly and disfiguring disease that could greatly benefit from new diagnostic approaches enabling early detection. In this pilot study, we describe a nano-bio-chip (NBC) sensor technique for analysis of oral cancer biomarkers in exfoliative cytology specimens, targeting both biochemical [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/nano-bio-chip-sensor-platform-for-examination-of-oral-exfoliative-cytology/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Epidermal growth factor receptor regulates beta-catenin location, stability, and transcriptional activity in oral cancer</title>
		<link>http://oralcancernews.org/wp/epidermal-growth-factor-receptor-regulates-beta-catenin-location-stability-and-transcriptional-activity-in-oral-cancer/</link>
		<comments>http://oralcancernews.org/wp/epidermal-growth-factor-receptor-regulates-beta-catenin-location-stability-and-transcriptional-activity-in-oral-cancer/#comments</comments>
		<pubDate>Mon, 22 Mar 2010 15:59:51 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[beta-catenin]]></category>
		<category><![CDATA[EGFR]]></category>
		<category><![CDATA[epidermal growth factor receptor]]></category>
		<category><![CDATA[malignancy]]></category>
		<category><![CDATA[marker]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=8173</guid>
		<description><![CDATA[
			
				
			
		
Source: 7thspace.com/headlines
Author: staff
Many cancerous cells accumulate beta-catenin in the nucleus. We examined the role of epidermal growth factor receptor (EGFR) signaling in the accumulation of beta-catenin in the nuclei of oral cancer cells.
Results:
We used two strains of cultured oral cancer cells, one with reduced EGFR expression (OECM1 cells) and one with elevated EGFR expression (SAS [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/epidermal-growth-factor-receptor-regulates-beta-catenin-location-stability-and-transcriptional-activity-in-oral-cancer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>New DNA therapy for advanced mouth cancer</title>
		<link>http://oralcancernews.org/wp/new-dna-therapy-for-advanced-mouth-cancer/</link>
		<comments>http://oralcancernews.org/wp/new-dna-therapy-for-advanced-mouth-cancer/#comments</comments>
		<pubDate>Sun, 07 Feb 2010 16:42:31 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[antisense]]></category>
		<category><![CDATA[DNA]]></category>
		<category><![CDATA[EGFR]]></category>
		<category><![CDATA[epidermal growth factor receptor]]></category>
		<category><![CDATA[protein]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=7832</guid>
		<description><![CDATA[
			
				
			
		
Source: www.dentistry.co.uk
Author: staff
A research team has been awarded a patent after developing a new DNA therapy for head and neck cancer sufferers. Researchers from the University of Pittsburgh School of Medicine in the US,  aims to develop a safe and effective alternative to standard chemotherapy treatments which cause debilitating side-effects.
Based on a form of [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/new-dna-therapy-for-advanced-mouth-cancer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pitt researchers receive patent for new head and neck cancer treatment</title>
		<link>http://oralcancernews.org/wp/pitt-researchers-receive-patent-for-new-head-and-neck-cancer-treatment/</link>
		<comments>http://oralcancernews.org/wp/pitt-researchers-receive-patent-for-new-head-and-neck-cancer-treatment/#comments</comments>
		<pubDate>Sun, 31 Jan 2010 13:34:56 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[antisense]]></category>
		<category><![CDATA[cetuximab]]></category>
		<category><![CDATA[cisplatin]]></category>
		<category><![CDATA[EGFR]]></category>
		<category><![CDATA[epidermal growth factor receptor]]></category>
		<category><![CDATA[genetic therapy]]></category>
		<category><![CDATA[radiation]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=7804</guid>
		<description><![CDATA[
			
				
			
		
Source: www.healthcanal.com
Author: staff
Researchers from the University of Pittsburgh School of Medicine have been awarded a patent from the U.S. Patent and Trademark Office for the development of a new DNA therapy for head and neck cancers. The therapy targets the epidermal growth factor receptor (EGFR), a protein found on the surface of many types of [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/pitt-researchers-receive-patent-for-new-head-and-neck-cancer-treatment/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Presence of rash associated with improved survival in patients receiving adjuvant Erbitux® for locally advanced head and neck cancer</title>
		<link>http://oralcancernews.org/wp/presence-of-rash-associated-with-improved-survival-in-patients-receiving-adjuvant-erbitux%c2%ae-for-locally-advanced-head-and-neck-cancer/</link>
		<comments>http://oralcancernews.org/wp/presence-of-rash-associated-with-improved-survival-in-patients-receiving-adjuvant-erbitux%c2%ae-for-locally-advanced-head-and-neck-cancer/#comments</comments>
		<pubDate>Wed, 18 Nov 2009 02:52:02 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[cetuximab]]></category>
		<category><![CDATA[EGFR]]></category>
		<category><![CDATA[epithelial growth factory receptor]]></category>
		<category><![CDATA[erbitux]]></category>
		<category><![CDATA[monoclonal antibody]]></category>
		<category><![CDATA[radiotherapy]]></category>
		<category><![CDATA[rash]]></category>
		<category><![CDATA[survival]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=7393</guid>
		<description><![CDATA[
			
				
			
		
Source: professional.cancerconsultants.com
Author: staff
A multicenter randomized trial has shown that patients with locoregionally advanced head and neck cancer receiving adjuvant Erbitux® (cetuximab) and radiotherapy who develop a rash have a better survival than patients receiving this therapy who don’t develop a rash.  The details of this five-year follow-up of a Phase III randomized study were [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/presence-of-rash-associated-with-improved-survival-in-patients-receiving-adjuvant-erbitux%c2%ae-for-locally-advanced-head-and-neck-cancer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>YM Biosciences reports positive nimotuzumab four-year survival data</title>
		<link>http://oralcancernews.org/wp/ym-biosciences-reports-positive-nimotuzumab-four-year-survival-data/</link>
		<comments>http://oralcancernews.org/wp/ym-biosciences-reports-positive-nimotuzumab-four-year-survival-data/#comments</comments>
		<pubDate>Tue, 03 Nov 2009 15:17:42 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[antibody]]></category>
		<category><![CDATA[cetuximab]]></category>
		<category><![CDATA[chemoradiotherapy]]></category>
		<category><![CDATA[EGFR]]></category>
		<category><![CDATA[nimotuzumab]]></category>
		<category><![CDATA[Phase III trial]]></category>
		<category><![CDATA[radiotherapy]]></category>
		<category><![CDATA[toxicity]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=7166</guid>
		<description><![CDATA[
			
				
			
		
Source: www.reuters.com
Author: press release
YM BioSciences Inc., a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, announced that an oral presentation at the American Society for Therapeutic Radiology and Oncology (ASTRO) 2009 Annual Meeting reported positive 48-month survival data for its EGFR-targeting antibody, [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/ym-biosciences-reports-positive-nimotuzumab-four-year-survival-data/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Erbitux® may improve treatment of squamous cell carcinoma of the esophagus</title>
		<link>http://oralcancernews.org/wp/erbitux%c2%ae-may-improve-treatment-of-squamous-cell-carcinoma-of-the-esophagus/</link>
		<comments>http://oralcancernews.org/wp/erbitux%c2%ae-may-improve-treatment-of-squamous-cell-carcinoma-of-the-esophagus/#comments</comments>
		<pubDate>Sat, 03 Oct 2009 14:26:31 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[5-FU]]></category>
		<category><![CDATA[chimeric monoclonal antibody]]></category>
		<category><![CDATA[cisplatin]]></category>
		<category><![CDATA[EGFR]]></category>
		<category><![CDATA[erbitux]]></category>
		<category><![CDATA[esophagus]]></category>
		<category><![CDATA[Platinol]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=6783</guid>
		<description><![CDATA[
			
				
			
		
Source: professional.cancerconsultants.com
Author: staff
Researchers from Germany have reported that Erbitux® (cetuximab) improves response rate, time to disease progression, and overall survival of patients with metastatic squamous cell carcinoma receiving Platinol® (cisplatin) and 5-FU. The details of this study appeared in the October 2009 issue of Annals of Oncology.[1]
Esophageal cancer is relatively common and is very deadly. [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/erbitux%c2%ae-may-improve-treatment-of-squamous-cell-carcinoma-of-the-esophagus/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Tips on managing the rash associated with EGFR inhibitors</title>
		<link>http://oralcancernews.org/wp/tips-on-managing-the-rash-associated-with-egfr-inhibitors/</link>
		<comments>http://oralcancernews.org/wp/tips-on-managing-the-rash-associated-with-egfr-inhibitors/#comments</comments>
		<pubDate>Mon, 28 Sep 2009 10:53:00 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[EGFR]]></category>
		<category><![CDATA[hydrocortisone]]></category>
		<category><![CDATA[Medrol Dosepak]]></category>
		<category><![CDATA[metronidazole cream]]></category>
		<category><![CDATA[rash]]></category>
		<category><![CDATA[secondary superinfection]]></category>
		<category><![CDATA[treatment algorithm]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=6722</guid>
		<description><![CDATA[
			
				
			
		
Source: OncologySTAT (www.oncologystat.com)
Author: OncologySTAT Editorial Team
Nurses at Duke University Hospital in Durham, NC, have developed a treatment algorithm for the rash that frequently occurs with use of epidermal growth factor receptor (EGFR) inhibitors. “We want to help sustain patients so they can continue to get their therapy and maintain their quality of life,” Kimberly Bishop, [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/tips-on-managing-the-rash-associated-with-egfr-inhibitors/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Gefitinib shows promise as treatment for advanced head and neck cutaneous squamous cell carcinoma</title>
		<link>http://oralcancernews.org/wp/gefitinib-shows-promise-as-treatment-for-advanced-head-and-neck-cutaneous-squamous-cell-carcinoma/</link>
		<comments>http://oralcancernews.org/wp/gefitinib-shows-promise-as-treatment-for-advanced-head-and-neck-cutaneous-squamous-cell-carcinoma/#comments</comments>
		<pubDate>Wed, 15 Jul 2009 11:04:14 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[diarrhoea]]></category>
		<category><![CDATA[EGFR]]></category>
		<category><![CDATA[epidermal growth factor receptor]]></category>
		<category><![CDATA[gefitinib]]></category>
		<category><![CDATA[skin rashes]]></category>
		<category><![CDATA[tyrosine kinase]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=6245</guid>
		<description><![CDATA[
			
				
			
		
Source: www.docguide.com
Author: Louise Gagnon
Gefitinib produces a significant response in patients with advanced head and neck cutaneous squamous cell carcinoma (cSCC) prior to standard treatment, according to a phase 2 study presented here at the 2nd World Congress of the International Academy of Oral Oncology (IAOO).
&#8220;We want to shrink the tumour as much as we can [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/gefitinib-shows-promise-as-treatment-for-advanced-head-and-neck-cutaneous-squamous-cell-carcinoma/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Vanderbilt-Ingram Cancer Center&#8217;s research efforts highlighted at annual cancer conference</title>
		<link>http://oralcancernews.org/wp/vanderbilt-ingram-cancer-centers-research-efforts-highlighted-at-annual-cancer-conference/</link>
		<comments>http://oralcancernews.org/wp/vanderbilt-ingram-cancer-centers-research-efforts-highlighted-at-annual-cancer-conference/#comments</comments>
		<pubDate>Sat, 27 Jun 2009 22:28:04 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[BRAFV600E]]></category>
		<category><![CDATA[EGFR]]></category>
		<category><![CDATA[epidermal growth factor receptor]]></category>
		<category><![CDATA[genetic mutation]]></category>
		<category><![CDATA[MAP kinase signaling pathway]]></category>
		<category><![CDATA[PLX4032]]></category>
		<category><![CDATA[tumor shrinkage]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=6114</guid>
		<description><![CDATA[
			
				
			
		
Source: www.mc.vanderbilt.edu
Author: Dagny Stuart
A new drug which targets a genetic mutation found in more than 50 percent of melanoma cases, 10 percent to 15 percent of colorectal tumors and 8 percent of other solid tumors, caused tumor shrinkage and extended progression-free survival among patients during a recent Phase 1 clinical trial. 
Igor Puzanov, M.D., assistant [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/vanderbilt-ingram-cancer-centers-research-efforts-highlighted-at-annual-cancer-conference/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>DNA therapy for head and neck cancer</title>
		<link>http://oralcancernews.org/wp/dna-therapy-for-head-and-neck-cancer/</link>
		<comments>http://oralcancernews.org/wp/dna-therapy-for-head-and-neck-cancer/#comments</comments>
		<pubDate>Wed, 03 Jun 2009 00:45:23 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[cetuximab]]></category>
		<category><![CDATA[EGFR]]></category>
		<category><![CDATA[erlotinib]]></category>
		<category><![CDATA[monotherapy]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=5990</guid>
		<description><![CDATA[
			
				
			
		
Source: Nature Reviews Clinical Oncology 6, 302 (June 2009)
Author: Mandy Aujla
Researchers have developed an antisense EGFR sequence to target EGFR, and found that this approach was safe and effective in patients with advanced squamous-cell carcinoma of the head and neck.
Standard treatment for this type of cancer is suboptimal. Various drugs have been developed to block [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/dna-therapy-for-head-and-neck-cancer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Personalised cancer diagnosis</title>
		<link>http://oralcancernews.org/wp/personalised-cancer-diagnosis/</link>
		<comments>http://oralcancernews.org/wp/personalised-cancer-diagnosis/#comments</comments>
		<pubDate>Wed, 13 May 2009 19:57:59 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[EGFR]]></category>
		<category><![CDATA[epidermal growth-factor receptors]]></category>
		<category><![CDATA[fluorescence resonance-energy transfer]]></category>
		<category><![CDATA[fluorescent dye]]></category>
		<category><![CDATA[FRET]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=5895</guid>
		<description><![CDATA[
			
				
			
		
Source: www.economist.com
Author: staff
If researchers could identify what it is that makes a tissue tumorous, they might be able to develop drugs aimed precisely at the cause of the cancer. At present, they know that certain molecules become active in tumours found in certain parts of the body. Both head-and-neck cancers and breast cancers, for example, [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/personalised-cancer-diagnosis/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Monoclonal Antibody Drugs for Cancer Treatment</title>
		<link>http://oralcancernews.org/wp/monoclonal-antibody-drugs-for-cancer-treatment/</link>
		<comments>http://oralcancernews.org/wp/monoclonal-antibody-drugs-for-cancer-treatment/#comments</comments>
		<pubDate>Sun, 05 Apr 2009 18:28:05 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[angiogenesis]]></category>
		<category><![CDATA[antibody-dependent cell-mediated cytotoxicity]]></category>
		<category><![CDATA[apoptosis]]></category>
		<category><![CDATA[Avastin]]></category>
		<category><![CDATA[bevacizumab]]></category>
		<category><![CDATA[cetuximab]]></category>
		<category><![CDATA[complement proteins]]></category>
		<category><![CDATA[cytotoxic agent]]></category>
		<category><![CDATA[effector cells]]></category>
		<category><![CDATA[EGFR]]></category>
		<category><![CDATA[epidermal growth factor receptor]]></category>
		<category><![CDATA[erbitux]]></category>
		<category><![CDATA[Herceptin]]></category>
		<category><![CDATA[hybridoma]]></category>
		<category><![CDATA[monoclonal antibodies]]></category>
		<category><![CDATA[nanogenerator]]></category>
		<category><![CDATA[proteins]]></category>
		<category><![CDATA[radioactive isotope]]></category>
		<category><![CDATA[rituximab]]></category>
		<category><![CDATA[Trastuzumab]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=3326</guid>
		<description><![CDATA[
			
				
			
		
Source: www.newswise.com
Author: staff
The strategy of using monoclonal antibodies for cancer treatment was first described in the late 1970s with the promise that they could be developed into therapies that were highly specific to cancer cells, killing them with few or no side effects. For several types of cancer, monoclonal antibodies have already offered this advantage [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/monoclonal-antibody-drugs-for-cancer-treatment/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Tarceva® and Avastin® safe and effective for patients with squamous-cell head and neck carcinoma</title>
		<link>http://oralcancernews.org/wp/tarceva%c2%ae-and-avastin%c2%ae-safe-and-effective-for-patients-with-squamous-cell-head-and-neck-carcinoma/</link>
		<comments>http://oralcancernews.org/wp/tarceva%c2%ae-and-avastin%c2%ae-safe-and-effective-for-patients-with-squamous-cell-head-and-neck-carcinoma/#comments</comments>
		<pubDate>Sat, 07 Mar 2009 05:41:40 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[Avastin]]></category>
		<category><![CDATA[bevacizumab]]></category>
		<category><![CDATA[EGFR]]></category>
		<category><![CDATA[epidermal growth factor receptor]]></category>
		<category><![CDATA[erlotinib]]></category>
		<category><![CDATA[humanized monoclonal antibody]]></category>
		<category><![CDATA[Tarceva]]></category>
		<category><![CDATA[vascular endothelial growth factor]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=1209</guid>
		<description><![CDATA[
			
				
			
		
Source: professional.cancerconsultants.com
Author: staff
Researchers from the National Cancer Institute and the University of Chicago have reported that the combination of Tarceva® (erlotinib) and Avastin® (bevacizumab) is well tolerated and produces sustained responses in some patients with recurrent or metastatic squamous-cell head and neck carcinoma. The details of this study appeared in the March 2009 issue of [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/tarceva%c2%ae-and-avastin%c2%ae-safe-and-effective-for-patients-with-squamous-cell-head-and-neck-carcinoma/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
